Biopharmaceutical benchmarks 2010
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Direct conversion of fibroblasts to functional neurons by defined factors
Vierbuchen, T., Ostermeier, A., Pang, Z. P., Kokubu, Y., Südhof, T. C., & Wernig, M. (2010) · Nature · doi:10.1038/nature08797 · Cited by 3,017 · cited 1×
“Particularly noteworthy is the recent finding that fibroblasts can be converted directly into neurons through expression of just three cellular transcription factor”
BackgroundEvidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505
Post-translational modifications in the context of therapeutic proteins
Walsh, G., & Jefferis, R. (2006) · Nature Biotechnology · doi:10.1038/nbt1252 · Cited by 1,005
Self-citationHumanization of yeast to produce complex terminally sialylated glycoproteins
Hamilton, S. R., Davidson, R. C., Sethuraman, N., Nett, J. H., Jiang, Y., Rios, S., Bobrowicz, P., Stadheim, T. A., Li, H., Choi, B.-K., et al. (2006) · Science · doi:10.1126/science.1130256 · Cited by 511
Expression systems for therapeutic glycoprotein production
Durocher, Y., & Butler, M. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.008 · Cited by 386 · cited 1×
“as well as further media optimization and approaches to prolong the life span of cells in cultur”
BackgroundBiopharmaceutical benchmarks 2006
Walsh, G. (2006) · Nature Biotechnology · doi:10.1038/nbt0706-769 · Cited by 359
Self-citationSelection methods for high-producing mammalian cell lines
Browne, S. M., & Al-Rubeai, M. (2007) · Trends in Biotechnology · doi:10.1016/j.tibtech.2007.07.002 · Cited by 237
Drucker, D. J., Dritselis, A., & Kirkpatrick, P. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3148 · Cited by 181
Zhu, Y., Jiang, J.-L., Gumlaw, N. K., Zhang, J., Bercury, S. D., Ziegler, R. J., Lee, K., Kudo, M., Canfield, W. M., Edmunds, T., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.37 · Cited by 177
Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC.
Natsume, A., Niwa, R., & Satoh, M. (2009) · PubMed Central · Cited by 165
Cited by
Biopharmaceutical benchmarks 2014
Walsh, G. (2014) · Nature Biotechnology · doi:10.1038/nbt.3040 · Cited by 1,008
Self-citationAhmad, M., Hirz, M., Pichler, H., & Schwab, H. (2014) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-014-5732-5 · Cited by 989
Biopharmaceutical benchmarks 2018
Walsh, G. (2018) · Nature Biotechnology · doi:10.1038/nbt.4305 · Cited by 978
Self-citationRegenerative medicine: Current therapies and future directions
Mao, A. S., & Mooney, D. J. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508520112 · Cited by 941
Kim, J. Y., Kim, Y.-G., & Lee, G. M. (2012) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-011-3758-5 · Cited by 801
The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line
Xu, X., Nagarajan, H., Lewis, N. E., Pan, S., Cai, Z., Liu, X., Chen, W., Xie, M., Wang, W., Hammond, S., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1932 · Cited by 785
“Fucosylation Most mammals have five primary types of fucosyltransferases, classified by the linkages between fucose and their substrates: α(1,2), α(1,3), α(1,4), α(1,6) and protein O-fucosyltransferases (Supplementary Table 14 for the glycans fucosylated by each class).”
InfluentialSAbDab: the structural antibody database
Dunbar, J., Krawczyk, K., Leem, J., Baker, T., Fuchs, A., Georges, G., Shi, J., & Deane, C. M. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1043 · Cited by 674
Strategies for extended serum half-life of protein therapeutics
Kontermann, R. E. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.06.012 · Cited by 573
Biopharmaceutical benchmarks 2022
Walsh, G., & Walsh, E. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01582-x · Cited by 552
Self-citationTailoring nanocarriers for intracellular protein delivery
Gu, Z., Biswas, A., Zhao, M., & Tang, Y. (2011) · Chemical Society Reviews · doi:10.1039/c0cs00227e · Cited by 543
Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars
Berkowitz, S. A., Engen, J. R., Mazzeo, J. R., & Jones, G. B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3746 · Cited by 529
Recent advances in (therapeutic protein) drug development
Lagassé, H. A. D., Alexaki, A., Simhadri, V. L., Katagiri, N. H., Jankowski, W., Sauna, Z. E., & Kimchi-Sarfaty, C. (2017) · F1000Research · doi:10.12688/f1000research.9970.1 · Cited by 481
Introduction to current and future protein therapeutics: A protein engineering perspective
Carter, P. J. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.02.013 · Cited by 467
Costa, S., Almeida, A., Castro, A., & Domingues, L. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00063 · Cited by 450
Lewis, N. E., Liu, X., Li, Y., Nagarajan, H., Yerganian, G., O'Brien, E., Bordbar, A., Roth, A. M., Rosenbloom, J., Bian, C., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2624 · Cited by 380
Cell factories for insulin production
Baeshen, N. A., Baeshen, M. N., Sheikh, A., Bora, R. S., Ahmed, M. M. M., Ramadan, H. A. I., Saini, K. S., & Redwan, E. M. (2014) · Microbial Cell Factories · doi:10.1186/s12934-014-0141-0 · Cited by 359
Wilson, S. A., & Roberts, S. C. (2012) · Plant Biotechnology Journal · doi:10.1111/j.1467-7652.2011.00664.x · Cited by 358
Dimitrov, D. S. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-921-1_1 · Cited by 347
Bispecific antibodies: design, therapy, perspectives
Sedykh, S., Prinz, V., Buneva, V., & Nevinsky, G. (2018) · Drug Design, Development and Therapy · doi:10.2147/dddt.s151282 · Cited by 292
Rasala, B. A., & Mayfield, S. P. (2015) · Photosynthesis Research · doi:10.1007/s11120-014-9994-7 · Cited by 290
Protein secretion in Pichia pastoris and advances in protein production
Damasceno, L. M., Huang, C.-J., & Batt, C. A. (2012) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-011-3654-z · Cited by 282
Functional single-cell hybridoma screening using droplet-based microfluidics
Debs, B. E., Utharala, R., Balyasnikova, I. V., Griffiths, A. D., & Merten, C. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204514109 · Cited by 276
Detoxifying Escherichia coli for endotoxin-free production of recombinant proteins
Mamat, U., Wilke, K., Bramhill, D., Schromm, A. B., Lindner, B., Kohl, T. A., Corchero, J. L., Villaverde, A., Schaffer, L., Head, S. R., et al. (2015) · Microbial Cell Factories · doi:10.1186/s12934-015-0241-5 · Cited by 274
Production of biopharmaceutical proteins by yeast: Advances through metabolic engineering
Nielsen, J. (2013) · Bioengineered · doi:10.4161/bioe.22856 · Cited by 270
T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation
Jawa, V., Cousens, L. P., Awwad, M., Wakshull, E., Kropshofer, H., & De Groot, A. S. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.09.006 · Cited by 270
Single-use disposable technologies for biopharmaceutical manufacturing
Shukla, A. A., & Gottschalk, U. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2012.10.004 · Cited by 265
Hyaluronic Acid Bioconjugates for the Delivery of Bioactive Molecules
Mero, A., & Campisi, M. (2014) · Polymers · doi:10.3390/polym6020346 · Cited by 264
Ahn, W. S., & Antoniewicz, M. R. (2011) · Metabolic Engineering · doi:10.1016/j.ymben.2011.07.002 · Cited by 262
The use of mass spectrometry to analyze dried blood spots
Wagner, M., Tonoli, D., Varesio, E., & Hopfgartner, G. (2016) · Mass Spectrometry Reviews · doi:10.1002/mas.21441 · Cited by 262
Microbials for the production of monoclonal antibodies and antibody fragments
Spadiut, O., Capone, S., Krainer, F., Glieder, A., & Herwig, C. (2014) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.10.002 · Cited by 258
AGGRESCAN3D (A3D): server for prediction of aggregation properties of protein structures
Zambrano, R., Jamroz, M., Szczasiuk, A., Pujols, J., Kmiecik, S., & Ventura, S. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv359 · Cited by 253
Non-genetic engineering of cells for drug delivery and cell-based therapy
Wang, Q., Cheng, H., Peng, H., Zhou, H., Li, P. Y., & Langer, R. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.12.003 · Cited by 225
Pereira, S., Kildegaard, H. F., & Andersen, M. R. (2018) · Biotechnology Journal · doi:10.1002/biot.201700499 · Cited by 214
Protein delivery into cells using inorganic nanoparticle–protein supramolecular assemblies
Scaletti, F., Hardie, J., Lee, Y.-W., Luther, D. C., Ray, M., & Rotello, V. M. (2018) · Chemical Society Reviews · doi:10.1039/c8cs00008e · Cited by 208
Proteomic analysis of Chinese hamster ovary cells
Baycin-Hizal, D., Tabb, D. L., Chaerkady, R., Chen, L., Lewis, N. E., Nagarajan, H., Sarkaria, V., Kumar, A., Wolozny, D., Colao, J., et al. (2012) · Journal of Proteome Research · doi:10.1021/pr300476w · Cited by 178
The emerging CHO systems biology era: harnessing the ‘omics revolution for biotechnology
Kildegaard, H. F., Baycin-Hizal, D., Lewis, N. E., & Betenbaugh, M. J. (2013) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2013.02.007 · Cited by 165
Ahn, W. S., & Antoniewicz, M. R. (2013) · Metabolic Engineering · doi:10.1016/j.ymben.2012.10.001 · Cited by 160
Daramola, O., Stevenson, J., Dean, G., Hatton, D., Pettman, G., Holmes, W., & Field, R. (2014) · Biotechnology Progress · doi:10.1002/btpr.1809 · Cited by 134
“However, CHO remains the industrypreferred mammalian host for the commercial production of recombinant therapeutic proteins.(2) The popularity of CHO cells is attributed to their regulatory track record, capacity for high levels of protein expression, efficient and bioactive post-translational modification, and succes…”
BackgroundCorchero, J. L., Gasser, B., Resina, D., Smith, W., Parrilli, E., Vázquez, F., Abasolo, I., Giuliani, M., Jäntti, J., Ferrer, P., et al. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2012.09.001 · Cited by 133
Immunogenicity assessment during the development of protein therapeutics
Rosenberg, A. S., & Sauna, Z. E. (2018) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12810 · Cited by 131
Metabolic responses of CHO cells to limitation of key amino acids
Duarte, T. M., Carinhas, N., Barreiro, L. C., Carrondo, M. J. T., Alves, P. M., & Teixeira, A. P. (2014) · Biotechnology and Bioengineering · doi:10.1002/bit.25266 · Cited by 110
Proteins behaving badly: emerging technologies in profiling biopharmaceutical aggregation
Hamrang, Z., Rattray, N. J. W., & Pluen, A. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.05.004 · Cited by 75
Glycoengineering in CHO cells: advances in systems biology
Tejwani, V., Andersen, M. R., Nam, J. H., & Sharfstein, S. T. (2018) · Biotechnology Journal · doi:10.1002/biot.201700234 · Cited by 70
Jadhav, V., Hackl, M., Hernandez Bort, J. A., Wieser, M., Harreither, E., Kunert, R., Borth, N., & Grillari, J. (2012) · Biotechnology and Bioengineering · doi:10.1002/bit.24490 · Cited by 55
Planinc, A., Dejaegher, B., Vander Heyden, Y., Viaene, J., Van Praet, S., Rappez, F., Van Antwerpen, P., & Delporte, C. (2017) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2016-001022 · Cited by 41
Wyre, C., & Overton, T. W. (2014) · Journal of Industrial Microbiology and Biotechnology · doi:10.1007/s10295-014-1489-1 · Cited by 27
Hippach, M. B., Schwartz, I., Pei, J., Huynh, J., Kawai, Y., & Zhu, M. M. (2018) · Biotechnology Progress · doi:10.1002/btpr.2697 · Cited by 10
Size distribution analysis of residual host cell DNA fragments in lentivirus by CGE-LIF
Wang, W., Gao, T., Luo, J., Guo, L., Li, X., Li, Y., & Chen, H. (2023) · ELECTROPHORESIS · doi:10.1002/elps.202200218 · Cited by 7
“During the production of lentivirus, HEK-293 cells are mainly selected as host cells, and residual host cell DNA (HCD) was a process-related impurity that often present in final products [13].”
Background
Metadata
- Authors
- Walsh, G.
- Venue
- Nature Biotechnology
- Published
- 2010-09
- Volume
- 28
- Issue
- 9
- Pages
- 917-924
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W1967681366
- Cited by
- 756
- References
- 16
- FWCI
- 30.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.